Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
(1,2-benzoxazol-3-yl)acetic acid
-
(2,1,3-benzothiadiazol-5-yl)methanol
-
2-((4-chloro-2,6-difluorobenzyl)amino)-7-oxo-5-propyl-4,7-dihydropyrazolo[1,5-a]-pyrimidine-3-carbonitrile
oral administration of the compound significantly raises the circulating levels of the branched-chain amino acids leucine, isoleucine, and valine. Compound demonstrates a good dose response, with leucine increasing from 473 microM (basal level) to 1.2 mM in 100 mg/kg treated mice
2-(2-((4-(1H-pyrazol-3-yl)phenyl)carbamoyl)phenyl)acetic acid
-
2-(2-(5-methyl-4-oxo-3,4-dihydrothieno[2,3-d]pyrimidine-6-carboxamido)phenyl)acetic Acid
-
2-(4-(1H-pyrazol-3-yl)phenyl)-3,4-dihydroisoquinolin-1(2H)-one
-
2-(methanesulfonyl)-N-phenylbenzamide
-
2-ethoxy-5-methyl-7-oxo-4,7-dihydropyrazolo[1,5-a]-pyrimidine-3-carbonitrile
-
2-hydroxy-N-(1,2,3,4-tetrahydronaphthalen-1-yl)acetamide
-
2-oxo-3-methylvalerate
-
measured in the forward reaction, concentrations higher than 1.0 mM inhibits the enzyme
2-Oxohexanoate
inhibition of transamination by the oxo substrate at below 10 mM
2-oxoisovalerate
-
measured in the forward reaction, concentrations higher than 1.0 mM inhibits the enzyme
3,5-dimethyl-4-oxo-3,4-dihydrothieno[2,3-d]pyrimidine-6-carboxylic acid
-
3,5-dimethyl-4-oxo-N-phenyl-3,4-dihydrothieno[2,3-d]-pyrimidine-6-carboxamide
-
3,5-dimethyl-6-(piperidine-1-carbonyl)thieno[2,3-d]-pyrimidin-4(3H)-one
-
3-methyl-1,2,3,4-tetrahydroquinoline-8-sulfonamide
-
3-methyl-2-oxovalerate
enzyme TUZN1299 is inhibited by keto acceptors in substrate inhibition, the maximum activity toward 4-methyl-2-oxovalerate and 3-methyl-2-oxovalerate in the reaction with L-alanine is achieved at a concentration of keto acids 1 mM, at 20 mM the specific activity of the enzyme decreases by 60% and 80%, respectively
3-methyl-2-[(quinazolin-4-yl)sulfanyl]butanoic acid
-
3-phenylthiophene-2-carboxamide
-
4,4-dimethyl-2-oxovalerate
inhibition of transamination by the oxo substrate at below 10 mM
4-(1-oxo-3,4-dihydroisoquinolin-2(1H)-yl)benzamide
-
4-methyl-2-oxopentanoate
-
-
5-benzyl-7-oxo-4,7-dihydropyrazolo[1,5-a]pyrimidine-3-carbonitrile
-
5-bromo-N'-(phenylsulfonyl)-1-benzofuran-2-carbohydrazide
IC50: 0.0025 mM
5-bromo-N'-(phenylsulfonyl)-1H-indole-2-carbohydrazide
IC50: 0.015 mM
5-chloro-N'-(phenylsulfonyl)-1-benzofuran-2-carbohydrazide
IC50: 0.0042 mM
5-chloro-N'-[(2-chlorophenyl)sulfonyl]-1-benzofuran-2-carbohydrazide
IC50: 0.0057 mM
5-chloro-N'-[(2-methylphenyl)sulfonyl]-1-benzofuran-2-carbohydrazide
IC50: 0.00116 mM
5-chloro-N'-[(3-methylphenyl)sulfonyl]-1-benzofuran-2-carbohydrazide
IC50: 0.0012 mM
5-chloro-N'-[[2-(trifluoromethyl)phenyl]sulfonyl]-1-benzofuran-2-carbohydrazide
IC50: 0.0008 mM, potent inhibitor
5-ethyl-2-methyl-7-oxo-4,7-dihydropyrazolo[1,5-a]pyrimidine-3-carbonitrile
-
5-methoxy-N'-(phenylsulfonyl)-1-benzofuran-2-carbohydrazide
IC50: 0.0128 mM
5-methoxy-N'-(phenylsulfonyl)-1H-indole-2-carbohydrazide
IC50: 0.0568 mM
5-methyl-4-oxo-3,4-dihydrothieno[2,3-d]pyrimidine-6-carboxylic acid
-
5-methyl-4-oxo-N-(1,3,4-thiadiazol-2-yl)-3,4-dihydrothieno-[2,3-d]pyrimidine-6-carboxamide
-
5-methyl-4-oxo-N-(2-sulfamoylphenyl)-3,4-dihydrothieno-[2,3-d]pyrimidine-6-carboxamide
-
5-methyl-4-oxo-N-(m-tolyl)-3,4-dihydrothieno[2,3-d]-pyrimidine-6-carboxamide
-
5-methyl-4-oxo-N-(o-tolyl)-3,4-dihydrothieno[2,3-d]-pyrimidine-6-carboxamide
-
5-methyl-4-oxo-N-(p-tolyl)-3,4-dihydrothieno[2,3-d]-pyrimidine-6-carboxamide
-
5-methyl-4-oxo-N-(pyridin-3-yl)-3,4-dihydrothieno[2,3-d]-pyrimidine-6-carboxamide
-
5-methyl-4-oxo-N-(thiophen-2-yl)-3,4-dihydrothieno[2,3-d]-pyrimidine-6-carboxamide
-
5-methyl-4-oxo-N-phenyl-3,4-dihydrothieno[2,3-d]-pyrimidine-6-carboxamide
-
5-methyl-N-(2-(methylsulfonyl )phenyl)-4-oxo-3,4-dihydrothieno[2,3-d]pyrimidine-6-carboxamide
-
6-phenoxypyridazin-3-amine
-
acetonitril
over 90% inhibition at 20-30%
benzothiazolyl-L-cysteine
D-cycloserine
DCS, mechanism-based inhibition of the Mycobacterium tuberculosis branched-chain aminotransferase by D-cycloserine, mechanism and enzyme-bound three-dimensional structure with a role of residue C196, overview. Time and concentration-dependent inactivation. The structure of the covalent D-cycloserine-PMP adduct bound to MtIlvE reveals that the D-cycloserine ring is planar and aromatic
DL-Penicillamine
residual activity 79%
DMSO
40% inhibition at 20%, 70% inhibition at 30%
ethyl 2-(2-(5-methyl-4-oxo-3,4-dihydrothieno[2,3-d]-pyrimidine-6-carboxamido)phenyl)acetate
-
Fe2+
-
1 mM, 34% residual activity
Hg2+
-
1 mM, 0% residual activity
Isocaproic acid
-
competitive inhibitor
isoleucine
-
competitive inhibition of enzyme activity with leucine
L-Cycloserine
LCS, mechanism-based inhibition of the Mycobacterium tuberculosis branched-chain aminotransferase by L-cycloserine, mchanism overview, time and concentration-dependent inactivation
L-cysteine
-
10 mM, inhibits activity with isoleucine and tyrosine by 22 and 34%, respectively
L-glutamate
inhibition of transamination by the oxo substrate at above 200 mM
L-isoleucine
-
with 1 mM tyrosine as the substrate, 10 mM isoleucine inhibits activity by 94%
L-leucine
-
with 1 mM tyrosine as the substrate, 10 mM leucine inhibits activity by 93%
L-methionine
-
10 mM methionine inhibits the activity with 1 mM tyrosine and phenylalanine by 86 and 59%, respectively, but it has no effect on the isoleucine activity
L-phenylalanine
-
with 2 mM isoleucine as the substrate, 10 mM phenylalanine inhibits activity by 46%
L-valine
-
with 1 mM tyrosine as the substrate, 10 mM valine inhibits activity by 78%
methanol
65% inhibition at 20%, 85% inhibition at 30%
N'-(phenylsulfonyl)-1-benzofuran-2-carbohydrazide
IC50: 0.0183 mM
N'-(phenylsulfonyl)-1H-indole-2-carbohydrazide
IC50: 0.036 mM
N'-(phenylsulfonyl)dibenzo[b,d]furan-2-carbohydrazide
IC50: 0.00235 mM
N'-(phenylsulfonyl)quinoline-3-carbohydrazide
IC50: 0.0333 mM
N'-(phenylsulfonyl)quinoline-6-carbohydrazide
IC50: 0.0133 mM
N'-[(2-chlorophenyl)sulfonyl]dibenzo[b,d]furan-2-carbohydrazide
IC50: 0.0129 mM
N'-[(2-methylphenyl)sulfonyl]dibenzo[b,d]furan-2-carbohydrazide
IC50: 0.0032 mM
N'-[(3-chlorophenyl)sulfonyl]dibenzo[b,d]furan-2-carbohydrazide
IC50: above 0.035 mM
N'-[(3-methylphenyl)sulfonyl]dibenzo[b,d]furan-2-carbohydrazide
IC50: 0.0028 mM
N'-[(4-chlorophenyl)sulfonyl]dibenzo[b,d]furan-2-carbohydrazide
IC50: 0.0372 mM
N'-[(4-methylphenyl)sulfonyl]dibenzo[b,d]furan-2-carbohydrazide
IC50: 0.051 mM
N-(2-(1H-pyrazol-3-yl)pyrimidin-5-yl)benzamide
-
N-(2-(hydroxymethyl)phenyl)-5-methyl-4-oxo-3,4-dihydrothieno[2,3-d]pyrimidine-6-carboxamide
-
N-(2-hydroxy-2-phenylethyl)urea
-
N-(4-(1H-pyrazol-3-yl)phenyl)benzamide
-
N-(4-carbamoylphenyl)-3,4-dichlorobenzamide
-
N-(4-carbamoylphenyl)benzamide
-
N-(isoxazol-3-yl)-5-methyl-4-oxo-3,4-dihydrothieno[2,3-d]-pyrimidine-6-carboxamide
-
N-(pyrimidin-5-yl)benzamide
-
N-cyclopentyl-3,5-dimethyl-4-oxo-3,4-dihydrothieno[2,3-d]-pyrimidine-6-carboxamide
-
O-(t-butyl)hydroxylamine
-
mixed-type inhibition, acts also as growth inhibitor of organism
O-allylhydroxylamine
-
mixed-type inhibition, acts also as growth inhibitor of organism
phenylpyruvate
-
shows substrate inhibition at 4 mM
S-(1,1,2,2-tetrafluoroethyl)-L-cysteine
-
rapidly inactivated by the beta-lyase substrate
S-(1,2-dichlorovinyl)-L-cysteine
-
rapidly inactivated by the beta-lyase substrate
S-(2-chloro-1,1,2-trifluoroethyl)-L-cysteine
-
rapidly inactivated by the beta-lyase substrate
trichloroethylene/dichloroacetylene
DCVC, selectively inhibits BCATc, resulting in suppressed transamination and subsequent neurotoxicity
valine
-
competitive inhibition of enzyme activity with leucine
[(3,6,7-trimethylquinolin-2-yl)sulfanyl]acetic acid
-
[1,1'-biphenyl]-2-carboxamide
-
[2-(phenylcarbamoyl)phenyl]acetic acid
-
2-Ketoglutarate
-
-
2-Ketoglutarate
-
17.5% activity in the presence of 10 mM
2-oxoglutarate
-
-
2-oxoglutarate
-
5 mM 2-oxoglutarate inhibits the transamination of the 6.3-fold purified enzyme, of valine and isoleucine by about 50%, but the leucine activity is less affected. Inhibition is competitive with respect to valine
2-oxoisocaproate
-
-
2-oxoisocaproate
-
measured in the forward reaction, concentrations higher than 1.0 mM inhibits the enzyme
4-methyl-2-oxovalerate
inhibition of transamination by the oxo substrate at below 10 mM
4-methyl-2-oxovalerate
enzyme TUZN1299 is inhibited by keto acceptors in substrate inhibition, the maximum activity toward 4-methyl-2-oxovalerate and 3-methyl-2-oxovalerate in the reaction with L-alanine is achieved at a concentration of keto acids 1 mM, at 20 mM the specific activity of the enzyme decreases by 60% and 80%, respectively
Aminooxyacetate
-
-
Aminooxyacetate
residual activity 79%
benzothiazolyl-L-cysteine
-
inhibits the L-leucine-2-oxoglutarate tranamination reaction of both isoenzymes
benzothiazolyl-L-cysteine
BTC, is a substrate and inactivator of BCATm but not BCATc, but BTC inhibits transamination between leucine and 2-oxoglutarate for both enzymes; BTC, is a substrate and inactivator of BCATm but not BCATc, but BTC inhibits transamination between leucine and 2-oxoglutarate for both enzymes. Inactivation of BCATm can occur through the interaction of aminoacrylate generated from the beta-lyase reaction with the PLP cofactor, through alkylation of a key residue at the active site, or through thioacylation by the eliminated sulphur-containing fragment
beta-chloro-L-alanine
-
rapidly inactivated by the beta-lyase substrate
beta-chloro-L-alanine
the compound is able to fit into the active site of BCATm, leading to inhibition of BCATm
carboxymethoxylamine
-
1 mM, 20% residual activity
carboxymethoxylamine
-
mixed-type inhibition, acts also as growth inhibitor of organism
Co2+
-
1 mM, 49% residual activity
Cu2+
-
1 mM, 39% residual activity
gabapentin
-
structural analogue of leucine, competitive inhibitor of BCATc, does not inhibit BCATm
gabapentin
inhibition is isoform-specific
gabapentin
-
inhibitor of the cytosolic enzyme
gabapentin
-
structural analogue of leucine, competitive inhibitor of BCATc, does not inhibit BCATm
HgCl2
-
-
hydrazine
-
-
hydroxylamine
-
-
hydroxylamine
-
1 mM, 3% residual activity
hydroxylamine
residual activity 72%
N-ethylmaleimide
-
-
O-Benzylhydroxylamine
-
mixed-type inhibition, acts also as growth inhibitor of organism
O-Benzylhydroxylamine
-
-
p-chloromercuribenzoate
-
isoenzyme I, complete inhibition, isoenzyme III only partially inhibited
p-chloromercuribenzoate
-
-
p-chloromercuribenzoate
-
-
p-chloromercuribenzoate
-
isoenzyme I, complete inhibition, isoenzyme III only partially inhibited
p-chloromercuribenzoate
-
-
p-chloromercuribenzoate
-
5 mM, complete inhibition
p-chloromercuribenzoate
-
-
p-chloromercuribenzoate
-
0.1 mM, complete inhibition
p-chloromercuribenzoate
-
-
phenylhydrazine
-
-
phenylhydrazine
-
1 mM, 0% residual activity
Semicarbazide
-
-
Semicarbazide
-
isoenzyme II is somewhat sensitive, isoenzyme I is not
Semicarbazide
residual activity 95%
ZnCl2
-
ZnCl2
-
5 mM, 50% inhibition
additional information
-
no inhibition with isonicotinic acid hydrazide or KCN
-
additional information
-
not inhibited by isonicotinic acid and semicarbazide
-
additional information
synthesis and evaluation of diverse inhibitors, pIC50 values, overview
-
additional information
-
not inhibitory: 4% NaCl, 1 mM iodoacetamide, 1 mM phenylmethylsulfonylfluoride
-
additional information
-
not inhibited by 5 mM KCI, NaCl, CuCl2, NiCl2, CoCl2, or FeCl2. No of activity with tyrosine by 10 mM aspartate, arginine, asparagine, glutamine, glycine, histidine, lysine, proline, serine, threonine or alanine
-
additional information
L-cycloserine is a 10fold better inhibitor of Mycobacterium tuberculosis growth than D-cycloserine. Both the D-cycloserine and L-cycloserine-PMP complexes have the same mass, and are likely to be the same aromatized, isoxazole product, but the kinetics of formation of the MtIlvE D-cycloserine-PMP and MtIlvE L-cycloserine-PMP adducts are quite different. While the kinetics of the formation of the MtIlvE D-cycloserine-PMP complex can be fit to a single exponential, the formation of the MtIlvE L-cycloserine-PMP complex occurs in two steps. No inhibition of the enzyme by propargylglycine (an inhibitor of cystathionine gamma-synthase), by gabaculine (an inhibitor of GABA aminotransferase and ornithine decarboxylase) or by difluoromethylornithine (DFMO, the inhibitor of ornithine decarboxylase). Also gabapentin, a potent inhibitor of the cytosolic isozyme hBCATc, has no effect on the activity of MtIlvE
-
additional information
-
L-cycloserine is a 10fold better inhibitor of Mycobacterium tuberculosis growth than D-cycloserine. Both the D-cycloserine and L-cycloserine-PMP complexes have the same mass, and are likely to be the same aromatized, isoxazole product, but the kinetics of formation of the MtIlvE D-cycloserine-PMP and MtIlvE L-cycloserine-PMP adducts are quite different. While the kinetics of the formation of the MtIlvE D-cycloserine-PMP complex can be fit to a single exponential, the formation of the MtIlvE L-cycloserine-PMP complex occurs in two steps. No inhibition of the enzyme by propargylglycine (an inhibitor of cystathionine gamma-synthase), by gabaculine (an inhibitor of GABA aminotransferase and ornithine decarboxylase) or by difluoromethylornithine (DFMO, the inhibitor of ornithine decarboxylase). Also gabapentin, a potent inhibitor of the cytosolic isozyme hBCATc, has no effect on the activity of MtIlvE
-
additional information
-
no inhibition with isonicotinic acid hydrazide or KCN
-
additional information
-
less than 10% inhibition with iodoacetamide, iodoacetate, sodium arsenite, oxidized glutathione, potassium ferricyanide, stannous chloride, ceric sulfate, aluminium chloride, cobalt chloride, ferric chloride, manganese chloride, magnesium chloride, calcium chloride or ferrous ammonium sulfate
-